TMPRSS2 and asthma: As expected, IL-17 treatment significantly increased expression of ACE2 and TMPRSS2 in a dose-dependent manner in both bronchial fibroblasts of severe asthma and healthy controls with no significant difference in their expression between the two groups (Supplementary Figure 2).